AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical trial titled ‘A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer.’ The study aims to evaluate the safety and tolerability of the drugs AZD2284, AZD2287, and AZD2275 in treating this aggressive form of prostate cancer.
The trial is testing three drugs: AZD2284, AZD2287, and AZD2275. These are administered via intravenous injection or infusion, and are designed to improve treatment outcomes for patients with metastatic castration-resistant prostate cancer.
This non-randomized, open-label study follows a sequential intervention model with no masking. Its primary purpose is treatment, focusing on determining optimal dosing and assessing safety and efficacy.
The study began on March 10, 2025, with its latest update submitted on July 22, 2025. These dates mark the study’s progress and ensure transparency in its development.
The market implications of this study are significant for AstraZeneca and its collaborators. Positive outcomes could enhance stock performance and investor confidence, especially in the competitive oncology market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.